Yohann Loriot

Research interests

Publications

• Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2312117

• Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2308849

• Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

  Nature Cancer · 2021 · https://doi.org/10.1038/s43018-021-00232-6

• Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · 10.1016/j.annonc.2021.11.012

• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00152-2

• Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2035807

• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00152-2

• TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03489

• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30541-6

• Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2002788

• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30541-6

• Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1817323

• Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

  Arthritis & Rheumatology · 2019 · https://doi.org/10.1002/art.41068

• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-019-0424-4

• TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

  Nature · 2018 · https://doi.org/10.1038/nature25501

• Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

  Annals of Oncology · 2017 · 10.1093/annonc/mdx518

• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

  Science · 2017 · https://doi.org/10.1126/science.aan3706

• Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33297-x

• High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-16-1396

• Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

  European Urology · 2016 · https://doi.org/10.1016/j.eururo.2016.07.032

• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

  The Lancet · 2016 · 10.1016/s0140-6736(16)32455-2

• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)00561-4

• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  Nature · 2014 · 10.1038/nature13904

• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1405095

• Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt136

• Abiraterone and Increased Survival in Metastatic Prostate Cancer

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1014618

Current projects

No projects listed.